Roche (OTCMKTS:RHHBY) Stock Price Passes Above 50-Day Moving Average - Time to Sell?

Key Points

• Roche shares crossed above their 50-day moving average, reaching $55.73 and last trading at $55.5250, compared with a 50-day average of $52.90.
• Analyst sentiment is mixed: Morgan Stanley upgraded Roche to “overweight” with a $63 target, while Zacks Research downgraded it to “strong sell” and HSBC lowered its rating to “hold.” The consensus rating is “Hold,” with an average price target of $60.
• Several institutional investors recently initiated or increased Roche positions, while the company reported moderate leverage with a debt-to-equity ratio of 0.72 and a current ratio of 1.38.

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report)'s share price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $52.90 and traded as high as $55.73. Roche shares last traded at $55.5250, with a volume of 3,983,664 shares trading hands.

Analysts Set New Price Targets

RHHBY has been the subject of a number of research reports. Zacks Research downgraded Roche from a "hold" rating to a "strong sell" rating in a report on Tuesday, July 14th. Morgan Stanley upgraded shares of Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price objective for the company in a research note on Friday, August 7th. Finally, HSBC cut shares of Roche from a "buy" rating to a "hold" rating in a report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $60.00.

Roche Stock Performance

The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. The company has a 50-day simple moving average of $52.90 and a 200 day simple moving average of $52.91.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. McIlrath & Eck LLC acquired a new stake in shares of Roche during the 1st quarter valued at about $39,000. Oakworth Capital Inc. grew its holdings in Roche by 20.8% in the fourth quarter. Oakworth Capital Inc. now owns 1,658 shares of the company's stock valued at $86,000 after purchasing an additional 285 shares during the period. Atlas Capital Advisors Inc. purchased a new stake in shares of Roche in the fourth quarter valued at approximately $192,000. Pinnacle Wealth Management Advisory Group LLC acquired a new position in shares of Roche during the 1st quarter worth approximately $208,000. Finally, Enterprise Financial Services Corp grew its stake in Roche by 6.6% in the 1st quarter. Enterprise Financial Services Corp now owns 5,576 shares of the company's stock valued at $277,000 after acquiring an additional 345 shares during the period.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source